Polyrizon completes enrollment of 120 patients in US NASARIX allergy study
PLRZ•Polyrizon completed enrollment and randomization of 120 participants across five U.S. sites in a controlled trial comparing its investigational nasal hydrogel NASARIX with saline in adults with allergic rhinitis.
1. Trial enrollment completed
Polyrizon completed enrollment and randomization of 120 participants across five U.S. sites. The randomized, controlled study compares NASARIX with saline in adults with allergic rhinitis; 144 individuals were screened to reach enrollment.
2. NASARIX design
NASARIX is an investigational nasal hydrogel designed to form a protective barrier in the nasal cavity and limit allergen contact with the nasal mucosa.
